Celldex Therapeutics, Inc (NASDAQ:CLDX) Delivers Positive Mast-Cell Data; Cash-Rich Position Extends Runway For Near-Term Catalysts
![]() |
Positive clinical readouts for mast-cell programs and a sizable equity raise position the company to advance multiple catalysts, though WMDST’s valuation classifies the stock as over-valued. |









